Switch theme
Sign up to access all valuation multiples
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
1999
14
Last FY Revenue $11K
Last FY EBITDA -$5.7M
$65.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Arovella Therapeutics achieved revenue of $11K and an EBITDA of -$5.7M.
Arovella Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arovella Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $11K | XXX | XXX | XXX |
| Gross Profit | XXX | $11K | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$5.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -51144% | XXX | XXX | XXX |
| EBIT | XXX | -$7.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -63596% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.8M | XXX | XXX | XXX |
| Net Margin | XXX | -51447% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, Arovella Therapeutics's stock price is AUD 0 (or $0).
Arovella Therapeutics has current market cap of AUD 111M (or $72.8M), and EV of AUD 98.8M (or $65.0M).
See Arovella Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65.0M | $72.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, Arovella Therapeutics has market cap of $72.8M and EV of $65.0M.
Arovella Therapeutics's trades at 467.2x EV/Revenue multiple, and -11.0x EV/EBITDA.
Equity research analysts estimate Arovella Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arovella Therapeutics's P/E ratio is not available.
See valuation multiples for Arovella Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $72.8M | XXX | $72.8M | XXX | XXX | XXX |
| EV (current) | $65.0M | XXX | $65.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 467.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -11.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -9.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -11.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArovella Therapeutics's revenue per employee in the last FY averaged $1K, while opex per employee averaged $0.5M for the same period.
Arovella Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arovella Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arovella Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 39620% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63696% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arovella Therapeutics acquired XXX companies to date.
Last acquisition by Arovella Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Arovella Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arovella Therapeutics founded? | Arovella Therapeutics was founded in 1999. |
| Where is Arovella Therapeutics headquartered? | Arovella Therapeutics is headquartered in Australia. |
| How many employees does Arovella Therapeutics have? | As of today, Arovella Therapeutics has 14 employees. |
| Is Arovella Therapeutics publicy listed? | Yes, Arovella Therapeutics is a public company listed on ASX. |
| What is the stock symbol of Arovella Therapeutics? | Arovella Therapeutics trades under ALA ticker. |
| When did Arovella Therapeutics go public? | Arovella Therapeutics went public in 2002. |
| Who are competitors of Arovella Therapeutics? | Similar companies to Arovella Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arovella Therapeutics? | Arovella Therapeutics's current market cap is $72.8M |
| Is Arovella Therapeutics profitable? | Yes, Arovella Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
